Latest news with #biosensing
Digital Trends
2 days ago
- Health
- Digital Trends
Blood oxygen measurement returns to the Apple Watch, sort of
Apple has just announced a software update that will enable the missing blood oxygen level measurement capability on the Apple Watch. The update will enable the biosensing feature on the Watch Series 9, Series 10, and the Apple Watch Ultra 2, once users update their iPhone and smartwatch to the latest build. What does it mean for users? In order to use the blood oxygen feature again on the Apple Watch Series 9, 10, and the Ultra 2, users will have to update their smartwatch to watchOS 11.6.1. The update is now rolling out to users in the United States. In addition to it, the feature will only work when users also update their iPhone to iOS 18.6.1, which has also been released simultaneously. Recommended Videos There's a crucial difference this time around. Instead of seeing the blood oxygen measurement on the Apple Watch screen, users will now have to open the Health app on their iPhone. That's because Apple is now doing the computation on the iPhone, instead of accomplishing it on the wearable and showing the results natively on the Apple Watch due to the patent dispute over alleged theft of the underlying pulse oximetry tech. 'Sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app,' instructs Apple. For all other Apple Watch models not affected by the patent dispute, they will continue to measure and show the measurements in the Blood Oxygen app on the smartwatch's screen. Why the hassle? So far, Apple Watch users have been able to track their blood oxygen saturation levels on their Apple Watch and see the readings on their wrists. But owing to a patent dispute with a company named Masimo and an import ban on models that offer this feature, the Cupertino-based company had to pull this capability after lengthy legal battles and an import ban handed down by the International Trade Commission The ban came into effect back in December of 2023, and despite a brief respite, Apple had to disable the blood oxygen features on the watches it sold following the trade restriction in the US. Apple has expressed disagreement with the charges leveled against it by Masimo, after the company filed two seprate lawsuits against the Apple Watch maker. Interestingly, Apple began working on a software-based workaround soon after the ITC ruling. It appears that the company was ready with an alternative route, but it's surprising that Apple took over a year and a half to enable it.
Yahoo
01-07-2025
- Business
- Yahoo
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
SAN DIEGO, July 01, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Category: IR View source version on Contacts DexCom, Inc.: Sean ChristensenVice President – Finance and Investor Relationsinvestor-relations@ (858) 200-0200
Associated Press
07-05-2025
- Health
- Associated Press
Nanophotonic sensing and label-free imaging of extracellular vesicles
GA, UNITED STATES, May 7, 2025 / / -- This review examines imaging-based nanophotonic biosensing and interferometric label-free imaging, with a particular focus on vesicle detection. It specifically compares dielectric and plasmonic metasurfaces for label-free protein and extracellular vesicle detection, highlighting their respective advantages and limitations. Proteins play a vital role in human health and detecting them is crucial in medical research and clinical practice. Protein assays are typically used to diagnose diseases, track disease progression, and assess treatment effectiveness. A growing area of interest is the detection of extracellular vesicles (EVs), nanoscale particles secreted by cells into bodily fluids. These vesicles present proteins that reflect their cell of origin and overall physiological state, making them valuable disease indicators. Because EVs can be collected from fluids rather than requiring invasive procedures like biopsies, they offer a promising way to monitor conditions like cancer in a minimally invasive manner. Traditionally, protein detection has relied on enzyme-linked immunosorbent assays (ELISA), which use antibodies to bind to specific proteins. However, ELISA has limitations, such as requiring precise antibody pairs, which are not always available. Additionally, labeling proteins with chemical markers can alter their natural structure and function, potentially affecting results and increasing costs. To overcome these challenges, the research community is exploring label-free detection methods. Advanced techniques such as surface plasmon resonance (SPR), photonic crystal resonance, interferometry, and nanoparticle tracking analysis enable the study of proteins and EVs in their natural state, reducing the risk of experimental interference. Label-free approaches also allow for real-time analysis, offering faster and more detailed insights compared to traditional methods. A particularly promising area of label-free detection is imaging-based nanophotonic sensing, which uses specially engineered surfaces to detect molecular interactions with high sensitivity. Within this field, dielectric and plasmonic metasurfaces are emerging as key technologies. Plasmonic systems are highly effective at detecting small molecules because they enhance electromagnetic fields at the nanoscale. Meanwhile, dielectric metasurfaces offer higher stability and precision and are ideal for analyzing EVs and larger biomolecules. Despite these advancements, challenges remain. The scientific community is working to improve surface chemistry approaches for more specific biomarker detection, develop cost-effective manufacturing methods, and integrate artificial intelligence to enhance data analysis. Further innovations in high-Q resonant structures—designed to optimize light-matter interactions—could lead to ultrasensitive, label-free biosensing and single-particle imaging. As these technologies improve, they have the potential to transform disease detection and monitoring, advancing both research and clinical applications. References DOI 10.1038/s41377-025-01866-2 Original Source URL Funding information This work was supported in part by National Institute of Health (NIH) 1U01CA279858, U01CA284982, R01CA239078, R01HL163513, R21CA267222, and R01CA264363. Lucy Wang BioDesign Research email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
